Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-01-2019 | Retinal Disorders

Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity

Authors: Emine Alyamaç Sukgen, Yusuf Koçluk

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 1/2019

Abstract

Purpose

To compare the results of ranibizumab and aflibercept treatment in infants with treatment-requiring retinopathy of prematurity (ROP) in the posterior zone.

Methods

In this single-center, retrospective study, the records of the infants, who were treated between January 2015 and June 2017 in a tertiary center for screening and treatment of ROP, were reviewed. Infants who were administered ranibizumab or aflibercept as initial treatment and completed at least 1 year of corrected age were included. The patients were evaluated in terms of regression, progression or recurrence of the disease, vascularization of the peripheral retina, and ocular complication profile in early or late period.

Results

Fifty-four eyes of 27 infants who received ranibizumab treatment (ranibizumab group) and 72 eyes of 36 infants who received aflibercept treatment (aflibercept group) were enrolled. The rate of recurrence was 48.1% in ranibizumab group and 13.9% in aflibercept group. The mean recurrence times were at 8.2 ± 0.92 weeks following the injection of ranibizumab and at 14.2 ± 1.03 weeks following the injection of aflibercept. There were significant statistical differences between the groups in the rate of ROP recurrence, the time of recurrence, and the time of vascularization of peripheral retina (p = 0.001, p < 0.001, p < 0.001, respectively).

Conclusion

Although both ranibizumab and aflibercept are effective therapies for the treatment of ROP, more frequent and much earlier recurrences can be seen with ranibizumab treatment. Further studies are needed to obtain ideal options for the treatment of ROP.

Gilbert C, Muhit M (2008) Twenty years of childhood blindness: what have we learned? Community eye health / International Centre for Eye Health 21(67):46–47

Blencowe H, Lawn JE, Vazquez T, et al. (2010) Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for. PediatrRes 2013;74 Suppl 1:35–49

Good WV, Early Treatment for Retinopathy of Prematurity Cooperative group (2004) Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 102:233–248PubMedPubMedCentral

Zhang G, Yang M, Zeng J et al (2016) Shenzhen Screening for Retinopathy of Prematurity Cooperative group. Comparison of intravitreal injection of Ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina 37(4):710–717CrossRef

Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603–615CrossRefPubMedPubMedCentral

Yetik H, Gunay M, Sirop S, Salihoglu Z (2014) Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27-month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol 14:334–339

The section on Ophthalmology, American Academy of Pediatrics; American Academy of Ophthalmology (2013) American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 131:189–195CrossRef

Martin DF, Maguire MG, Ying GS et al (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908CrossRefPubMed

International Committee for the Classification of Retinopathy of prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991–999CrossRef

10.

Salman AG, Said AM (2015) Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethresholdtype 1 retinopathy of prematurity. Ophthalmic Res 53(1):15–20. https://doi.org/10.1159/000364809 CrossRefPubMed

11.

Alyamac Sukgen E, Çömez A, Koçluk Y, Cevher S (2016) The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity:a comparison between Ranibizumab and bevacizumab. Ophthalmologica 236(3):139–147CrossRefPubMed

12.

Avery RL, Castellarin AA, Steinle NC et al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98:1636–1641CrossRefPubMed

13.

Wu WC, Shih CP, Lien R, Wang NK et al (2017) Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina 37(4):694–701CrossRefPubMed

14.

Ferrara N, Damico L, Shams N et al (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859–870CrossRefPubMed

15.

Erol MK, Coban DT, Sari ES et al (2015) Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol 78:340–343PubMed

16.

Zehetner C, Kralinger MT, Modi YS et al (2015) Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomized, prospective trial. Acta Ophthalmol 93:e154–e159CrossRefPubMed

17.

Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab, and bevacizumab. Angiogenesis 15:171–185CrossRefPubMedPubMedCentral

18.

Yi Z, Su Y, Zhou Y et al (2016) Effects of intravitreal Ranibizumab in the treatment of retinopathy of prematurity in Chinese infants. Curr Eye Res 41(8):1092–1097CrossRefPubMed

19.

Stewart MW, Rosenfeld PJ, Penha FM et al (2012) Pharmacokinetic rationale for dosing every2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept(vascular endothelial growth factor trapeze). Retina 32:434–457PubMed

20.

Hartnett ME (2014) Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity. Clin Perinatol 41:925–943CrossRefPubMedPubMedCentral

21.

Warden SM, Andreoli CM, Mukai S (2007) The Wnt signaling pathway in familial exudative vitreoretinopathy and Norrie disease. Semin Ophthalmol 22:211–217CrossRefPubMed

22.

Sondell M, Lundborg G, Kanje M (1999) Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 19:5731–5740CrossRefPubMedPubMedCentral

23.

Jin KL, Mao XO, Greenberg DA (2000) Vascular endothelial growth factor: direct neuroprotective effect in vitro ischemia. ProcNatl Acad Sci USA 97:10242–10247CrossRef

24.

Saint-Geniez M, Maharaj AS, Walshe TE et al (2008) Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One 3(11):e3554CrossRefPubMedPubMedCentral

25.

Zhou Y, Jiang Y, Bai Y et al (2015) Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol. https://doi.org/10.1007/S000417-015-2996-0

26.

Cam D, Berk AT, Micili SC et al (2016) Histological and Immunohistochemical retinal changes following the intravitreal injection of Aflibercept, bevacizumab, and Ranibizumab in newborn rabbits. Curr Eye Res 17:1–8

Title: Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity
Authors: Emine Alyamaç Sukgen
Yusuf Koçluk
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 1/2019
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-018-4168-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Hyperreflective foci in Stargardt disease: 1-year follow-up

Choriocapillaris flow features and choroidal vasculature in the fellow eyes of patients with acute central serous chorioretinopathy

Activation of the sweet taste receptor T1R3 by sucralose attenuates VEGF-induced vasculogenesis in a cell model of the retinal microvascular endothelium

Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial

Antibacterial and physical properties of a novel sonochemical-assisted Zn-CuO contact lens nanocoating

Novel clinical findings in autosomal recessive NR2E3-related retinal dystrophy